FDA Sends Interim Peptide Compounding Policy to White House Review

A federal policy that could reopen a legal path for some popular “wellness” peptides has reached the White House. On October 14, 2026, the White House regulatory review office received an FDA document titled “Interim Access Policy for Compounding Using Certain Peptides.” Its text has not been released, and nothing changes until FDA publishes it. Still, it is the clearest sign so far that the agency may act on this summer’s controversial advisory committee votes.

The filing matters for the research-peptide market, but it has clear limits. Retatrutide is not part of it, and based on legal analyses published so far, neither are products sold as “research use only.”

Key facts

• What happened: FDA’s interim peptide compounding policy went to the Office of Information and Regulatory Affairs (OIRA), part of the Office of Management and Budget, on October 14, 2026. It is listed as pending review.
• What’s public: Very little. The OIRA entry classifies the action as a notice with no legal deadline. It does not name the peptides covered or list any conditions.
• Background: In July 2026, FDA’s Pharmacy Compounding Advisory Committee recommended adding six peptides (BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax) to the list of bulk substances that pharmacies may compound under Section 503A.
• Current status: No peptide has been added to that list. The committee’s votes are recommendations only, and FDA’s own staff scientists had advised against all seven peptides under review.
• Not covered: Based on law-firm analyses, a likely interim policy would apply to state-licensed 503A pharmacies only. It would not reach research-use-only sellers, dietary supplements or 503B outsourcing facilities.

What FDA sent to the White House

The submission appears in OIRA’s public review records, and The Washington Times reported on October 16 that HHS was aiming to let pharmacies compound certain peptides. According to an analysis by the law firm Buchanan Ingersoll & Rooney, the record confirms that the policy is under executive review. It does not say when FDA will issue it or what the final version will contain.

Open questions include which peptides would qualify, whether only 503A pharmacies would be covered, and whether the policy would limit routes of administration or add sourcing, testing or reporting requirements. A Holland & Knight client alert says the most likely form is “enforcement discretion.” Under that approach, FDA would announce that it does not plan to act against licensed pharmacies compounding certain peptides for individual patients, as long as they meet set conditions. One possible step would be moving the peptides into Category 1 of FDA’s interim bulks policy.

Enforcement discretion would not make any peptide an approved drug, and FDA could narrow or withdraw it without a formal comment process.

How the peptide review got here

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, a pharmacy may compound from a bulk ingredient only if the ingredient is part of an FDA-approved drug, has an official monograph or appears on the 503A bulks list. In 2023, FDA placed BPC-157, TB-500 and other peptides in Category 2, its label for substances that raise significant safety concerns.

The situation shifted in 2026:

• February 27: HHS Secretary Robert F. Kennedy Jr. publicly backed broader access to these peptides.
• April 15: FDA said it would take 12 peptides out of Category 2 after their nominations were withdrawn, and it scheduled an advisory committee review.
• June 29: FDA staff briefing documents recommended against listing any of the seven peptides under review. They cited poorly characterized substances, little or no human clinical data and safety concerns such as immune reactions. The same day, FDA announced a reconstituted advisory committee.
• July 23–24: The committee voted for six peptides and against emideltide (DSIP). BPC-157, KPV and TB-500 each passed 8–6 with one abstention.

Permanent listing still requires a proposed rule, public comment and a final rule, and no deadline applies. Holland & Knight notes that an earlier FDA rule on 10 bulk substances took from 2016 to 2019 to finalize. A second committee meeting on five more peptides (GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF) is expected by the end of February 2027, though FDA hasn’t set a date.

A likely legal fight

An interim policy would go against the advice of FDA’s own scientific reviewers. Pharmaceutical trade groups have already told the committee that FDA cannot lawfully allow compounding through a stopgap while rulemaking is still pending. Holland & Knight reads those comments as a preview of a possible court challenge. Buchanan Ingersoll & Rooney adds that state pharmacy boards will still govern day-to-day pharmacy practice, whatever FDA decides.

Enforcement is moving the other way

The access debate is unfolding alongside tougher enforcement. On August 24, 2026, FDA sent warning letters to five online peptide vendors. The letters concluded that “research use only” labels did not outweigh evidence of intended human use, such as bacteriostatic water sold alongside the peptides and dosing calculators on the vendors’ sites. On September 18, a separate warning letter said a compounder’s GLP-1 products with added B12 or niacinamide were essentially copies of approved drugs.

Retatrutide sits entirely outside the compounding debate. It is an investigational drug that is not FDA-approved. According to Holland & Knight, its developer filed six lawsuits against sellers in August 2026 and made more than 200 referrals to regulators and law enforcement. Medscape reports that Eli Lilly plans to file its approval application for retatrutide with FDA in the first quarter of 2027. Our retatrutide trial results explainer summarizes the clinical data published so far.

What this means for researchers and buyers

• Nothing has changed legally yet. The policy is under review, its text is not public, and no peptide has been added to the 503A bulks list.
• The research-use-only market is not part of this. Based on available analyses, any interim access would run through prescriptions filled by licensed pharmacies. It would not cover research-chemical sellers, and FDA’s recent warning letters show that a “research use only” label offers limited protection.
• Retatrutide is a separate case. It is not among the peptides under compounding review, and it remains investigational and not FDA-approved.
• Quality documentation still matters most. For lab buyers, independent testing, clear certificates of analysis and accurate labeling remain the main markers of a vendor’s credibility. These are the criteria behind how we rate vendors, and you can compare individual sellers in our vendor reviews.

Next, watch whether OIRA clears the policy, which peptides it names and what conditions FDA attaches.